HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Gain Therapeutics (NASDAQ:GANX) and maintained a $10 price target.
August 14, 2023 | 10:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on Gain Therapeutics and maintained a $10 price target.
The reiteration of a 'Buy' rating and maintenance of a $10 price target by HC Wainwright & Co. is a positive signal for Gain Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100